Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

Bullboard Posts

Post by Gustoeson May 17, 2019 1:11pm

80 Views

Post# 29756230

2.3 logs, 99.5% kill rate against HT1376

xray for bladder in the future??

As a result of the observed synergy, total PDT-induced cell kill could be increased achieving 2.3 logs (99.5%) cell kill of cancer cells that could not be obtained separately with light or X-rays (Table 8).

https://patentscope.wipo.int/search/en/detail.jsf?docId=US205400727&tab=PCTDESCRIPTION&office=&prevFilter=&sortOption=Pub+Date+Desc&queryString=PA%3Atheralase&recNum=7&maxRec=27

TABLE 8

Dark cell kill (%), PDT cell kill (%) and pure PDT effect (% cell kill,
in brackets) induced in HT1376 cells by 80 μM TLD1433 using
near infrared light (808 nm, 600 J cm⁻²), X-ray irradiation
(5 Gy, 225 KeV) and combined irradiation.

				X-ray &	Near
Concen-		Near		Near	Infrared &
tration	Dark	Infrared	X-ray	Infrared	X-ray

0 uM	0.0	24.6	28.3	40.7	46.3
80 uM	2.3	45.9 (19.0)	66.4 (35.8)	99.5 (56.5)	71.3 (22.7)

Example 3

Premixing of the photosensitizers with transferrin (Tf) improves their selective uptake into tumor cells and potentially improves X-ray mediated PDT effect. Ruthenium based TLD1433 (80 μM) and human apo-Tf (5 μM) were used to assess the effect of Tf on visible light or X-ray mediated PDT effect on U87 (human glioblastoma) and HT1376 (human urinary bladder carcinoma) cell cultures.

Bullboard Posts

Advancing flagship Ishkõday Gold Project in Ontario